Glonghui, April 11 | Lyon published a research report saying that the mainland has continuously introduced policies on innovative drugs in recent weeks, and it has been seen that investors' confidence in innovative drug manufacturers has improved. In the mainland clinical research industry, the bank believes that Tiger Pharmaceuticals and Zhaoyan New Pharmaceuticals can benefit more from the government's new support policy than their peers. The bank raised Tiger Pharmaceuticals's rating from “outperforming the market” to “outperforming the market”. The target price was raised from HK$31.4 to HK$37.3 as the transparency of its earnings growth would improve from FY2025. The bank also upgraded the new drug rating to “outperform the market”, and the target price was raised from HK$9.8 to HK$11.